Analysed PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) News Sources
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
09-04-2026
yahoo.com
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762
30-03-2026
yahoo.com
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement
23-03-2026
yahoo.com
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office
16-03-2026
yahoo.com
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
13-03-2026
yahoo.com
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
10-03-2026
yahoo.com
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
05-03-2026
yahoo.com
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
05-03-2026
yahoo.com
What is the current price of PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ)?
The current price of PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) is $1.21.
PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) absolute price change since previous trading day?
The absolute price change of PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) since the previous trading day is $-0.04.
PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) percentage price change since previous trading day?
The percentage price change of PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) since the previous trading day is -3.2%.
What is the most recent average sentiment score for PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ)?
The most recent average sentiment score for PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) is 87 out of 100.
What is the most recent average sentiment for PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ)?
The most recent sentiment for PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ) is .
SEC-8K** Filing Available For PHIO PHARMACEUTICALS CORP (PHIO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.